9th Annual PREDiCT: Tumor Models Cell Therapy Summit | July 13-15, 2021

With commitments to advancing your preclinical and translational oncology research, we are delighted to bring the 9th annual PREDiCT: Tumor Models Cell Therapy Summit to your screens in July.

See best-in-class tumor models and how they can be effectively utilized to model the tumor microenvironment and further your MoA understanding for new cell therapies.

Learn to improve your translational and clinical confidence through the use of models to answer critical safety and efficacy questions, predict toxicity and optimize dosing for patients.

Whether you work in early discovery or late development, there is something for all non-clinical professionals with two dedicated tracks: one focused on preclinical modelling and one looking at translational studies.

Below are a few highlights you won't want to miss!

- Novartis share how to use a simple xenograft model to effectively assess CAR-T efficacy
- AstraZeneca shows how to guide innovative clinical trials for cell therapies using preclinical data
- Takeda discuss how to leverage single-cell analytics to understand the complexities of the tumor microenvironment
- Harvard Medical School share how they use multiple tumor models to advance NK cell therapies

Get involved! Our scientific poster sessions will be returning this year so you can share your latest advances and be apart of the conversation.

URLs:
Tickets: https://go.evvnt.com/752399-2?pid=176
Brochure: https://go.evvnt.com/752399-3?pid=176

Prices:
Conference + 2 Workshops - Drug Developer (Early Booking Rates Available): USD 2699.0,
Conference + 1 Workshop - Drug Developer (Early Booking Rates Available): USD 2349.0,
Conference Only - Drug Developer (Early Booking Rates Available): USD 1999.0,
Conference + 2 Workshops - Academics (Early Booking Rates Available): USD 2399.0,
Conference + 1 Workshop - Academics (Early Booking Rates Available): USD 2099.0,
Conference Only - Academics (Early Booking Rates Available): USD 1799.0,
Conference + 2 Workshops - Model Developer and Service Provider (Early Booking Rates Available): USD 3299.0,
Conference + 1 Workshop - Model Developer and Service Provider (Early Booking Rates Available): USD 2899.0,
Conference Only - Model Developer and Service Provider (Early Booking Rates Available): USD 2499.0

Speakers: Ganesh Mugundu, Head of Cell Therapy Clinical Pharmacology and Modelling, Takeda, Rekha Pal, Director and Scientific Engagement, Crown Bioscience, Aaron Goldman, Director, Drug Resistance Group, Harvard Medical School, Jonathan Nakashima, Chief Scientific Officer, Certis Oncology Solutions, Markus Vallaster, Senior Medical Director, Cell Therapies and Immuno-Oncology, AstraZeneca, Senior Representative, The Jackson Laboratory, Mari Kuraguchi, Director, in vivo Pharmacology, Principal Scientist, Biocytogen, Kris Richardson, Senior Data Scientist, Berg Health, Natasha Darras, Director, Cell Therapy Translational Medicine, Takeda Oncology, Irena Adkins, Pharmacology and Science Lead, SOTIO, Shiva Kazerounian, Associate Director, Principal Scientist and Lead, In Vivo Pharmacology, Berg Health, Simone Filosto, Principal Scientist, Translational Research and Clinical Pharmacology, Kite Pharma, Chad May, Senior Vice President, Research and Development, Maverick Therapeutics, Boris Engels, Associate Director, Novartis, Principal Scientist, Bristol-Myers Squibb, Aman Singh, Associate Director, Clinical Pharmacology M and S, Takeda, Joshua Breunig, Associate Professor, Cedars-Sinai Medical Centre, Viswanathan Muthusamy, Research Scientist, Executive Director, Yale School of Medicine, Eric Ibsen, Chief Executive Officer, Studylog, Anton Neschadim, Chief Executive Officer and Director, ImmunoBiochem Corp, Yufei Wang, Research Fellow, Dana-Faber Cancer Institute, Kader Thiam, Senior Vice President Discovery - Preclinical Models and Services, GenOway, Sheri Barnes, Associate Director - Scientific Development, Covance, Rakesh Awasthi, Clinical Pharmacology, Pharmacokinetic Oncology Sciences and Investigator, Novartis, Martina Molgora, Postdoctoral Researcher, Washington University School of Medicine, Nikolaus Krall, Chief Executive Officer and Co-Founder, Allcyte, Astero Klampatsa, Team Leader, Institute of Cancer Research, John Maher, Senior Lecturer - Clinical Immunology, King's College London

Time: 08:30 - 18:30